At 4 months following infusion, we observed a decrease in autoantibodies without a decrease in vaccine or infectious disease-associated antibodies in agreement with other reports of autoimmune disease patients treated with CD19-CAR T cells (Figures 1F and 1G).13 The gene discussed is CD19; the disease is autoimmune disease.